Prostate Cancer Clinical Trial

Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

Summary

A phase1 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

histologically confirmed prostate cancer. known or suspected bone metastases referred for a clinical [99mTc]MDP scan

Exclusion Criteria:

Estimated creatinine clearance (GFR) < 30 mL/min (calculated), history of hyperparathyroidism, • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician, • Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

Study is for people with:

Prostate Cancer

Phase:

Early Phase 1

Estimated Enrollment:

14

Study ID:

NCT02826382

Recruitment Status:

Completed

Sponsor:

Five Eleven Pharma, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Pennsylvania
Philadelphia Pennsylvania, , United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Early Phase 1

Estimated Enrollment:

14

Study ID:

NCT02826382

Recruitment Status:

Completed

Sponsor:


Five Eleven Pharma, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.